anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided herein are radiopharmaceutical compositions, conjugates and uses thereof. In one aspect, provided herein are covalently modified KRAS proteins comprising a radiolabeled compound or conjugate. In some embodiments, the radiolabeled compound described herein comprises a covalently bound radioisotope. In some embodiments, the radiolabeled conjugate comprises a targeting ligand and a metal chelator configured to bind a radionuclide. The radiolabeled compound or conjugate described herein can form a covalent bond with a cysteine residue (such as G12C) in the mutated KRAS protein. Further provided herein are methods of treating and diagnosing cancer by administering the described radiolabeled compounds, conjugates, and compositions to a subject, thereby forming the covalently modified KRAS G12C protein.
A process for the production of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol F (Tafemidis meglumine) comprising the step of cyclization of 4-(3,5-dichlorobenzamido)-3-hydroxybenzoic acid D in the presence of acetic acid and a sulfonic acd to yield the Tafamidis acetic acid adduct E followed by adduct exchange with N-Methyl-D-Glucamine; precipitation and drying of the precipitate to give Tafamidis meglumine. The process is preferably conducted in glacial acetic acid, and the sulfonic acid is preferably p-toluenesulfonic acid. The temperature of the process is preferably below 125°C. The process preferably comprises the additional step of contacting the obtained Tafamidis meglumine with an aprotic solvent with successive removal of the solvent to yield crystalline Tafamidis meglumine. A crystalline form of Tafamidis meglumine is also disclosed characterized by powder X-ray diffraction peaks at 12.2, 23.0 and 25.5 (2θ ± 0.2; which may further comprise peaks at 5.5, 17.2 and 24.7. Pharmaceutical compositions comprising the crystalline form are disclosed, and their use in the treatment of familial amyloid polyneuropathy (FAP), familial transthyretin (TTR) amyloidosis or transthyretin familial amyloid polyneuropathy.
PROBLEM TO BE SOLVED: To obtain the subject agent freed from side effects without lowering antipyretic/analgesic/anti-inflammatory activities inherent in the subject compound as an active ingredient by including a specific compound having aconitine- type chemical structure and an acetylcholine antagonist. SOLUTION: This medicinal agent is obtained by including (A) a compound having aconitine-type chemical structure of the formula (R1 is H or OH; R2 is OH, acetyloxy or a group capable of forming carbonyl together with the carbon atom at 15-position; R3 is H, a 1-4C alkyl, acetyl or propionyl; R4 is H, OH or acetyloxy) (e.g. 15-O-acetyl-14-O-p-chlorobenzoylmesaconine) and (B) an acetylcholine antagonist (esp. a parasympathetic blocking agent, among others antimuscarinic agent, typically anthropine or the like). The dosage form of this agent may be such one that the above ingredients are integrally pharmaceutically manufactured together with a vehicle, or separately pharmaceutically manufactured into a kit form. The single dose of this agent is 0.1-10 mg/adult.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Patients should take the drug as prescribed, in the dosage prescribed, and no more frequently than prescribed.

Patients should be informed that changes in vision should be reported and evaluated. Retinal examinations including optical coherence tomography (OCT) and auto-fluorescence imaging are suggested for all patients within six months of starting ELMIRON ®and periodically during long-term treatment (see WARNINGS). 

Patients should be reminded that ELMIRON ®has a weak anticoagulant effect. This effect may increase bleeding times.
Endoscopic ultrasound (EUS) - guided fine needle aspiration (FNA) is a well-established technique for tissue sampling of intestinal and extra-intestinal mass lesions. The accuracy of EUS-guided FNA varies from 60% - 100% with a complication rate of 0% - 3%. The diagnostic accuracy of the procedure can be improved by the use immunohistochemical studies and genetic analyses.It may also be improved by obtaining a larger biopsy specimen with a core biopsy needle. However, puncturing with a core-biopsy needle may not be always feasible due to the technical difficulty of inserting the larger needle through the bended endoscope. As a result, the advantage of a core-biopsy needle on providing a larger amount of cellular material is offset by a higher rate of technical failures, especially in the setting of a transduodenal puncture. Recently, a new 22G FNA needle with a reverse bevel at the tip has become available (ECHO-HD-22-C, Cook Endoscopy, USA.). The design of the device promotes the collection of core samples by shearing material from target lesion during retrograde movement of the needle in the lesion. Hence, the aim of this study is to compare the tissue-sampling rate and the diagnostic accuracy rate of EUS-FNA using 22G conventional and Procore needles.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, oncology, and can be used for photodynamic therapy of superficial spreaded bladder carcinoma. For this purpose, 2 hours prior to the laser esposure, the chemopreparation Mitomycin C in dosage 40 mg in 50 ml of 0.9% physiologic saline is introduced in the bladder cavity. The laser exposure follows through an intracystic optical fluid medium. ^ EFFECT: method allows higher clinical antineoplastic effectiveness ensured by enlarged desmosomal spaces of tumour tissues that simplify chemopreparation transport, the presence of the photosensitiser in the tumour cells promotes maximum concentration of the chemopreparation in the tumour in relation to the normal mucosa, as well as prolonged exposure of the chemopreparation on the tumour, potentiated effect of the photodynamic therapy on the tumour. ^ 2 ex
A parenteral nutritional diagnostic system, apparatus, and method are disclosed. In an example, a parenteral nutritional diagnostic apparatus determines muscle quantity and muscle quality of a patient's psoas muscle to determine a nutritional status of the patient. An image interface is configured to receive a medical image including radiodensity data related to imaged tissue of the patient. The apparatus also includes a processor configured to use the medical image to determine a tissue surface area for each different value of radiodensity and determine a distribution of the tissue surface area for each radiodensity value. The processor is configured to determine muscle quality by locating a soft tissue peak within the distribution that corresponds to a local peak in at a region related to at least one of muscle tissue, organ tissue, and intramuscular adipose tissue. The processor determines the nutritional status of the patient based on the soft tissue peak.
PURPOSE:To obtain a pyrazolotriazole derivative which is useful as a raw material for medicine, by reacting a pyrazole compound with an ortho-acid ester to give a product which is then N-alkylated, further reacted with hydroxylamine and finally ring closed. CONSTITUTION:A compound of the formula I (where, R<1> is H, a lower alkyl) with a compound of the formula R<1>-C(OR<2>)3 (where, R<2> is a lower alkyl), are reacted to obtain an imidate of the formula II. Then, the compound of the formula II is reacted with a compound of the formula III (where, X<1>, X<2> are each a halogen (s)) to give an N-alkylated compound of the formula IV. Then, the compound of the formula IV is reacted with hydroxylamine to give a compound of the formula V, then the compound of the formula V is ring closed to give the objective compound of the formula VI. The compound of the formula VI is useful as a raw material for a pyrazolotriazole compound having angiotensin II antagonism. The compounds of the formula II, IV and V are novel synthetic intermediate compounds.
BACKGROUND: There is no optimal reconstruction method after proximal gastrectomy. The valvuloplastic esophagogastrostomy can reduce postoperative reflux esophagitis, but it is technically complex with a long operation time. The gastric tube anastomosis is technically simple, but the incidences of reflux esophagitis and anastomotic stricture are higher.
METHODS: We have devised a modified valvuloplastic esophagogastrostomy after laparoscopy-assisted proximal gastrectomy (LAPG), the arch-bridge anastomosis. After reviewing our prospectively maintained gastric cancer database, 43 patients who underwent LAPG from November 2021 to April 2023 were included in this cohort study, with 25 patients received the arch-bridge anastomosis and 18 patients received gastric tube anastomosis. The short-term outcomes were compared between the two groups to evaluate the efficacy of the arch-bridge anastomosis. Reporting was consistent with the STROCSS 2021 guideline.
RESULTS: The median operation time was 180 min in the arch-bridge group, significantly shorter than the gastric tube group (p = 0.003). In the arch-bridge group, none of the 25 patients experienced anastomotic leakage, while one patient (4%) experienced anastomotic stricture requiring endoscopic balloon dilation. The postoperative length of stay was shorter in the arch-bridge group (9 vs. 11, p = 0.034). None of the patients in the arch-bridge group experienced gastroesophageal reflux and used proton pump inhibitor (PPI), while four (22.2%) patients in the gastric tube group used PPI (p = 0.025). The incidence of reflux esophagitis (Los Angeles grade B or more severe) by endoscopy was lower in the arch-bridge group (0% vs. 25.0%).
CONCLUSION: The arch-bridge anastomosis is a safe, time-saving, and feasible reconstruction method. It can reduce postoperative reflux and anastomotic stricture incidences in a selected cohort of patients undergoing laparoscopy-assisted proximal gastrectomy.
The method for treating the patients with late rheumatoid arthritis provides for monotherapy with one of the basic drugs (Methotrexate, Leflunomid, Sulfasalasin) or the combined basic therapy. The drugs are selected based on the contraindications for Methotrexate as well as other initial laboratory parameters. When antibody to cyclic citrullinated peptide is detected, Leflunomid or the combined basic therapy is provided irrespective of other laboratory findings. In seronegative patients, Methotrexate or Leflunomid or the combined basic therapy is provided. In case of the absence of erosive patterns in X-ray films and the absence of the systemic manifestations, any variant of the basic therapy is appropriate. In the case of the absence of erosive patterns in X-ray films in the patients with systemic manifestations, one should consider the use of Methotrexate or Leflunomid.
This is a single-dose and multiple-dose, open-label, single-centre pharmacokinetic (PK) study, to evaluate pharmacokinetics (PK) of different levels of single-dose and multiple-dose of bilastine in healthy Chinese subjects. Total 24 subjects will be enrolled into the study and divided into 2 cohorts, 12 subjects in each cohort.

Single-dose only cohort treatment duration is 1 day and receive a single dose of 40 mg of bilastine then collect PK blood sample. Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9 and collect PK blood samples. The primary objective of the study is to determine the PK properties of orally administered bilastine in healthy Chinese population. The secondary objective of the study is to evaluate the safety and tolerability of bilastine administered as a single and multiple doses in healthy Chinese subjects.
INTRODUCTION: It is known that symptoms of major depressive disorder (MDD) are associated with neurodegeneration, that lipopolysaccharide (LPS) can induce symptoms of MDD, and that blood LPS levels are elevated in neurodegeneration. However, it is not known whether blood LPS and cytokine levels correlate with MDD, cognition and brain structure, and this is tested in this study.
METHODS AND ANALYSIS: This cross-sectional study includes individuals with MDD (n = 100) and a control group of individuals with no one-year history of a mental disorder (n = 50). A comprehensive evaluation is performed, including the collection of basic sociodemographic information, data on smoking status, body mass index, course of MDD, past treatment, comorbid diseases, and current use of medications. Diagnosis of MDD is performed according to the WHO's [2019] International Classification of Diseases and related health problems by psychiatrist and severity of MDD is evaluated using the Montgomery-Åsberg Depression Scale. The Cambridge Neuropsychological Test Automated Battery is used to evaluate cognitive functioning. Venous blood samples are taken to measure genetic and inflammatory markers, and multiparametric brain magnetic resonance imaging is performed to evaluate for blood-brain barrier permeability, structural and neurometabolic brain changes. Descriptive and inferential statistics, including linear and logistic regression, will be used to analyse relationships between blood plasma LPS and inflammatory cytokine concentrations in MDD patients and controls. The proposed sample sizes are suitable for identifying significant differences between the groups, according to a power analysis.
ADMINISTRATIVE INFORMATION: Trial registration: Clinicaltrials.gov NCT06203015.
The present invention relates to a Chinese medicine effervescent tablet for treating cerebral apoplexy, namely a cerebral embolism effervescent tablet, and a preparation method thereof. The preparation method adopts a direct tablet pressing method to press the effervescent tablet and the prescription of the cerebral embolism effervescent tablet contains cerebral embolism dry extract, crospovidone, mannitol, anhydrous citric acid, sodium bicarbonate, microcrystalline cellulose, silica gel powder, magnesium stearate, talcum powder and aspartame. The pressure range of a plain tablet is from 5.5N to 12.5N, disintegration time can reach 2'12', and effervescent time can reach 3'50'. The plain tablet is coated by blue film coating materials and a coated instant tablet is a special-shaped table with the disintegration time of 3'56' and the effervescent time of 6'16'. The effervescent tablet prepared by the method does not need taking with water and can be quickly dissolved when coming into contact with sputum in the mouth and partial medicines can be absorbed by blood through the transference of the mouth cavity, the sublingual gland and the tunica mucosa linguae. The effervescent tablet has the advantages of quick effect action, high medical absorption and biological availability, convenient oral application and little stimulation on the esophagus and the gastrointestinal tract.
An aqueous adjuvant composition comprising an attenuated lipid A derivative and a surfactant or surfactants enhances the immunological response in a warm blooded animal to a protein antigen.  Attenuated lipid A derivatives useful according to the subject invention include monophosphoryl lipid A and 3-O-deacylated monophosphoryl lipid A. A surfactant or mixtures of surfactants are dissolved in a solvant. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine is a preferred surfactant. The dissolved surfactant is added to an attenuated lipid A derivative to obtain a mixture. The molar ratio of attenuated lipid A  derivative to surfactant in the mixture is about 4:1. The solvent is evaporated and water is added to the resulting film. The suspension is sonicated in a 60 °C water bath until it becomes clear.  Animals administered the adjuvant formulation exhibited increased antibody responses to a given antigen as well as displayed enhanced lymphocyte proliferative and cytotoxic T-lymphocyte responses. Intranasal administration of the aqueous adjuvant composition and an antigen stimulates the production of serum and mucosal secreted IgA.
BACKGROUND: Acute post-streptococcal glomerulonephritis (APSGN) is a common cause of acute kidney injury (AKI) in children; however, in a small subgroup, the presentation is one of rapidly progressive glomerulonephritis (RPGN) deteriorating kidney function associated with severe oligo-anuria or a mixed nephritic-nephrotic picture. This study reviewed potential clinical and laboratory factors which may assist the treating clinician to identify patients at high risk of severe disease.
METHODS: All kidney biopsies for APSGN performed between 1996 and 2020 were obtained from a departmental biopsy database. Clinical and laboratory data were extracted from the patients' clinical records. Kidney biopsies were reviewed and scored independently by a renal histopathologist.
RESULTS: Thirty of 53 (56.6%) patients had stage 3 AKI at initial presentation with a median estimated glomerular filtration rate (eGFR) 27 (IQR 11-41), falling to 20 ml/min/1.73 m2 (IQR 13.3-43) at time of biopsy. Patients who had either a pre-biopsy eGFR < 35 ml/min/1.73 m2 or a ≥ 25% fall in eGFR between admission and biopsy were more likely to have glomerular crescents (p = 0.004). Multivariate regression analysis and receiver operating curve showed the pre-biopsy eGFR most accurately predicted glomerular crescents (p = 0.047, ROC 0.757). There were no significant predictors of nephrotic proteinuria or nephrotic syndrome during the acute phase.
CONCLUSIONS: Severe APSGN is associated with a pronounced reduction in eGFR. Calculation of eGFR in this small group of patients may assist in identifying which patient should have an urgent kidney biopsy to facilitate a more accurate clinical diagnosis and management plan.
Currently, in the United Kingdom, the recommended method for diagnostic testing and screening for COVID-19 is quantitative (real-time) reverse transcription polymerase chain reaction (PCR) analysis of viral RNA extracted from upper respiratory tract samples. A positive result indicates that SARS-CoV-2 RNA has been detected with a cycle threshold (Ct) value of less than 38 cycles of amplification (n.b. this is a locally agreed value, which is based on analysis of proficiency testing performance and other local testing data. Cycle threshold (Ct) values inversely correlate to the amount of target nucleic acid in the sample. Thus, a lower cycle threshold (Ct) value indicates a greater amount of target nucleic acid in a sample i.e. a higher viral load.

A recent scoping literature review has revealed only a handful of published studies to date that explore an association between cycle threshold (Ct) values and disease severity or clinical outcome in patients infected with the SARS-CoV-2 virus. The majority of these studies have been conducted in China with small patient sample sizes. Thus, a larger-scale study which explores the relationship between viral load and disease severity is required; indeed, the World Health Organization (WHO) has recently highlighted this as an area which needs further research.
Exercise devices typically assume that a user can walk or stand to maintain balance with a floor or wall mounted design. Devices made for the elderly/infirm are mainly used to relax muscles by creating a series of movements. When sports become life lines of extended life, it is often too cumbersome or complex to set for the elderly. There is a need for a new invention that is compact, lightweight, low cost, and portable as shown in fig. 1A. It provides operability in a risk-free environment and is self-sufficient. It includes an adjustable resistance function to gradually reestablish the strength of skeletal muscle. This is a simple device that can provide a whole body exercise (even a separate limb, and a core area), simulating walking movements, which can be the best overall exercise to maintain health. Restoring the walking ability of the old and breaking the dependence of the old on the wheelchair.
Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
OBJECTIVES: Electrocardiogram (ECG) and measurement of plasma brain natriuretic peptides (BNP) are established markers of right ventricular dysfunction (RVD) in the setting of acute pulmonary embolism (PE) but their value at long-term follow-up is largely unknown. The purpose of this prospective study was to determine the prevalence of ECG abnormalities, describe levels of N-terminal proBNP (NT-proBNP), and establish their association with dyspnea at long-term follow-up after PE.
DESIGN: All Swedish patients diagnosed with acute PE in 2005 (n = 5793) were identified through the Swedish National Patient Registry. Surviving patients in 2007 (n = 3510) were invited to participate. Of these, 2105 subjects responded to a questionnaire about dyspnea and comorbidities. Subjects with dyspnea or risk factors for development of chronic thromboembolic pulmonary hypertension were included in the study in a secondary step, which involved collection of blood samples and ECG registration.
RESULTS: Altogether 49.3% had a completely normal ECG. The remaining participants had a variety of abnormalities, 7.2% had atrial fibrillation/flutter (AF). ECG with any sign of RVD was found in 7.2% of subjects. Right bundle branch block was the most common RVD sign with a prevalence of 6.4%. An abnormal ECG was associated with dyspnea. AF was associated with dyspnea, whereas ECG signs of RVD were not. 61.2% of subjects had NT-proBNP levels above clinical cut-off (>125 ng/L). The degree of dyspnea did not associate independently with NT-proBNP levels.
CONCLUSIONS: We conclude that the value of ECG and NT-proBNP in long term follow-up after PE lies mostly in differential diagnostics.
BACKGROUND/AIMS: Ischemic reperfusion (I-R) injury is greatly influenced by the testicular torsion/detorsion process (TDP). In this instance, the anti-inflammatory properties of plateletrich plasma (PRP) combined with tadalafil (Td) significantly promote tissue healing in the I-R injury model.
METHODS: Five groups of rats were created: the control group, the I-R group not receiving any therapy, the I-R group receiving a single dosage of Td (0.25 mg/kg, I.P.), the I-R group receiving a single dose of PRP (80 l, intratesticular), and the I-R group receiving both Td and PRP. Sperm morphology, motility, and histology were assessed. The levels of TNF-, BAX, antioxidant status, and testosterone were measured. Additionally, E-selectin expression was done.
RESULTS: PRP reduced oxidative stress, inflammation, and apoptosis while also boosting testosterone levels, which alleviated I-R injury. Otherwise, PRP reduces E-selectin expression, which modifies the pathways that control endothelial function. Td also partially demonstrated its testicular-protective activity at the same time.
CONCLUSION: PRP's proven anti-inflammatory, antioxidant, and antiapoptotic potentials make it a natural treatment for testicular harm caused by tadalafil. For the first time, it was demonstrated that PRP therapy restored the functionality of the vascular endothelium, specifically the control of E-selectin expression. Combining Td and PRP therapy may be a promising strategy for improving response to PDE5 inhibitors.